Bioengineered Liver Models for Drug Testing and Cell Differentiation Studies

Gregory H. Underhill, Salman R. Khetani

Research output: Contribution to journalReview article

Abstract

In vitro models of the human liver are important for the following: (1) mitigating the risk of drug-induced liver injury to human beings, (2) modeling human liver diseases, (3) elucidating the role of single and combinatorial microenvironmental cues on liver cell function, and (4) enabling cell-based therapies in the clinic. Methods to isolate and culture primary human hepatocytes (PHHs), the gold standard for building human liver models, were developed several decades ago; however, PHHs show a precipitous decline in phenotypic functions in 2-dimensional extracellular matrix–coated conventional culture formats, which does not allow chronic treatment with drugs and other stimuli. The development of several engineering tools, such as cellular microarrays, protein micropatterning, microfluidics, biomaterial scaffolds, and bioprinting, now allow precise control over the cellular microenvironment for enhancing the function of both PHHs and induced pluripotent stem cell–derived human hepatocyte-like cells; long-term (4+ weeks) stabilization of hepatocellular function typically requires co-cultivation with liver-derived or non–liver-derived nonparenchymal cell types. In addition, the recent development of liver organoid culture systems can provide a strategy for the enhanced expansion of therapeutically relevant cell types. Here, we discuss advances in engineering approaches for constructing in vitro human liver models that have utility in drug screening and for determining microenvironmental determinants of liver cell differentiation/function. Design features and validation data of representative models are presented to highlight major trends followed by the discussion of pending issues that need to be addressed. Overall, bioengineered liver models have significantly advanced our understanding of liver function and injury, which will prove useful for drug development and ultimately cell-based therapies.

Original languageEnglish (US)
Pages (from-to)426-439.e1
JournalCMGH
Volume5
Issue number3
DOIs
StatePublished - Mar 2018

Fingerprint

Cell Differentiation
Liver
Pharmaceutical Preparations
Hepatocytes
Cell- and Tissue-Based Therapy
Bioprinting
Organoids
Chemical and Drug Induced Liver Injury
Cellular Microenvironment
Protein Array Analysis
Preclinical Drug Evaluations
Microfluidics
Biocompatible Materials
Cues
Liver Diseases
Wounds and Injuries

Keywords

  • Bioprinting
  • Cellular Microarrays
  • Hepatocytes
  • Microfluidics
  • Micropatterned Co-Cultures
  • Spheroids

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Bioengineered Liver Models for Drug Testing and Cell Differentiation Studies. / Underhill, Gregory H.; Khetani, Salman R.

In: CMGH, Vol. 5, No. 3, 03.2018, p. 426-439.e1.

Research output: Contribution to journalReview article

Underhill, Gregory H. ; Khetani, Salman R. / Bioengineered Liver Models for Drug Testing and Cell Differentiation Studies. In: CMGH. 2018 ; Vol. 5, No. 3. pp. 426-439.e1.
@article{4fad167e00c543c987a90e3de7e3ac8b,
title = "Bioengineered Liver Models for Drug Testing and Cell Differentiation Studies",
abstract = "In vitro models of the human liver are important for the following: (1) mitigating the risk of drug-induced liver injury to human beings, (2) modeling human liver diseases, (3) elucidating the role of single and combinatorial microenvironmental cues on liver cell function, and (4) enabling cell-based therapies in the clinic. Methods to isolate and culture primary human hepatocytes (PHHs), the gold standard for building human liver models, were developed several decades ago; however, PHHs show a precipitous decline in phenotypic functions in 2-dimensional extracellular matrix–coated conventional culture formats, which does not allow chronic treatment with drugs and other stimuli. The development of several engineering tools, such as cellular microarrays, protein micropatterning, microfluidics, biomaterial scaffolds, and bioprinting, now allow precise control over the cellular microenvironment for enhancing the function of both PHHs and induced pluripotent stem cell–derived human hepatocyte-like cells; long-term (4+ weeks) stabilization of hepatocellular function typically requires co-cultivation with liver-derived or non–liver-derived nonparenchymal cell types. In addition, the recent development of liver organoid culture systems can provide a strategy for the enhanced expansion of therapeutically relevant cell types. Here, we discuss advances in engineering approaches for constructing in vitro human liver models that have utility in drug screening and for determining microenvironmental determinants of liver cell differentiation/function. Design features and validation data of representative models are presented to highlight major trends followed by the discussion of pending issues that need to be addressed. Overall, bioengineered liver models have significantly advanced our understanding of liver function and injury, which will prove useful for drug development and ultimately cell-based therapies.",
keywords = "Bioprinting, Cellular Microarrays, Hepatocytes, Microfluidics, Micropatterned Co-Cultures, Spheroids",
author = "Underhill, {Gregory H.} and Khetani, {Salman R.}",
year = "2018",
month = "3",
doi = "10.1016/j.jcmgh.2017.11.012",
language = "English (US)",
volume = "5",
pages = "426--439.e1",
journal = "Cellular and Molecular Gastroenterology and Hepatology",
issn = "2352-345X",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Bioengineered Liver Models for Drug Testing and Cell Differentiation Studies

AU - Underhill, Gregory H.

AU - Khetani, Salman R.

PY - 2018/3

Y1 - 2018/3

N2 - In vitro models of the human liver are important for the following: (1) mitigating the risk of drug-induced liver injury to human beings, (2) modeling human liver diseases, (3) elucidating the role of single and combinatorial microenvironmental cues on liver cell function, and (4) enabling cell-based therapies in the clinic. Methods to isolate and culture primary human hepatocytes (PHHs), the gold standard for building human liver models, were developed several decades ago; however, PHHs show a precipitous decline in phenotypic functions in 2-dimensional extracellular matrix–coated conventional culture formats, which does not allow chronic treatment with drugs and other stimuli. The development of several engineering tools, such as cellular microarrays, protein micropatterning, microfluidics, biomaterial scaffolds, and bioprinting, now allow precise control over the cellular microenvironment for enhancing the function of both PHHs and induced pluripotent stem cell–derived human hepatocyte-like cells; long-term (4+ weeks) stabilization of hepatocellular function typically requires co-cultivation with liver-derived or non–liver-derived nonparenchymal cell types. In addition, the recent development of liver organoid culture systems can provide a strategy for the enhanced expansion of therapeutically relevant cell types. Here, we discuss advances in engineering approaches for constructing in vitro human liver models that have utility in drug screening and for determining microenvironmental determinants of liver cell differentiation/function. Design features and validation data of representative models are presented to highlight major trends followed by the discussion of pending issues that need to be addressed. Overall, bioengineered liver models have significantly advanced our understanding of liver function and injury, which will prove useful for drug development and ultimately cell-based therapies.

AB - In vitro models of the human liver are important for the following: (1) mitigating the risk of drug-induced liver injury to human beings, (2) modeling human liver diseases, (3) elucidating the role of single and combinatorial microenvironmental cues on liver cell function, and (4) enabling cell-based therapies in the clinic. Methods to isolate and culture primary human hepatocytes (PHHs), the gold standard for building human liver models, were developed several decades ago; however, PHHs show a precipitous decline in phenotypic functions in 2-dimensional extracellular matrix–coated conventional culture formats, which does not allow chronic treatment with drugs and other stimuli. The development of several engineering tools, such as cellular microarrays, protein micropatterning, microfluidics, biomaterial scaffolds, and bioprinting, now allow precise control over the cellular microenvironment for enhancing the function of both PHHs and induced pluripotent stem cell–derived human hepatocyte-like cells; long-term (4+ weeks) stabilization of hepatocellular function typically requires co-cultivation with liver-derived or non–liver-derived nonparenchymal cell types. In addition, the recent development of liver organoid culture systems can provide a strategy for the enhanced expansion of therapeutically relevant cell types. Here, we discuss advances in engineering approaches for constructing in vitro human liver models that have utility in drug screening and for determining microenvironmental determinants of liver cell differentiation/function. Design features and validation data of representative models are presented to highlight major trends followed by the discussion of pending issues that need to be addressed. Overall, bioengineered liver models have significantly advanced our understanding of liver function and injury, which will prove useful for drug development and ultimately cell-based therapies.

KW - Bioprinting

KW - Cellular Microarrays

KW - Hepatocytes

KW - Microfluidics

KW - Micropatterned Co-Cultures

KW - Spheroids

UR - http://www.scopus.com/inward/record.url?scp=85043596460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043596460&partnerID=8YFLogxK

U2 - 10.1016/j.jcmgh.2017.11.012

DO - 10.1016/j.jcmgh.2017.11.012

M3 - Review article

AN - SCOPUS:85043596460

VL - 5

SP - 426-439.e1

JO - Cellular and Molecular Gastroenterology and Hepatology

JF - Cellular and Molecular Gastroenterology and Hepatology

SN - 2352-345X

IS - 3

ER -